Investigational Oral Drug Shows Promise in Genetic Bleeding Disorder

(MedPage Today) — Treatment with the investigational oral, allosteric, selective AKT inhibitor engasertib appeared to be safe in patients with hereditary hemorrhagic telangiectasia (HHT), and was associated with decreases in epistaxis frequency…